The New York Times Business section published an interesting article today about a group of medical students and faculty at Harvard Medical School pushing for greater disclosure of the relationship between pharmaceutical companies and faculty teachers. The article and the comments on the NYT web site raise an interesting discussion. Those who advocate full disclosure and even the removal of pharmaceutical money and interest in medical schools content that medical education must be objective and cannot be so if faculty members are paid by pharmaceutical companies. Others contend that pharmaceutical money, used responsibly, is absolutely necessary to support important medical research and innovation that is being conducted on medical school campuses across the country.
What do you think? How can pharmaceutical money be used by medical schools responsibly? Is it time to get pharmaceutical companies out of medical schools? Is that even possible?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment